Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Hyeokgeon Kwon
04.09.26 -- AI Assesses Passion At CDMOs, But Humans Think Differently
New data on process development strategies and tools Join us on 19-21 May - From upstream to downstream for protein-based and gene therapy processes. Attend one session or twenty. Click to explore the full agenda. What Biotech Startups Need To Know About Sterile Fill Finish Services Sterile fill–finish is a critical, tightly regulated stage for biotechs, demanding strong contamination control, smart CDMO selection, and awareness of capacity, scalability, and regulatory hurdles.
01.10.26 -- Bioprocess Online Best Of December
DECEMBER'S BEST FEATURED EDITORIAL Biotech Collaboration Strategy With IGI's Cyril Konto, M.D. Cyril Konto, CEO at Ichnos Glenmark Innovation, talks about the promise of multi-specific antibodies, funding the company during the 'biotech winter,' and closing a $700 million licensing deal with AbbVie.
12.23.25 -- Strained Manufacturing, Complexity Stymie In Vivo Progress
The 2026 ISPE Facilities of the Future Conference will provide actionable insights and real-world case study examples addressing key industry challenges and opportunities, from best practices in facility design, digital transformation, and emerging technologies, to sustainability initiatives, workforce development, and compliance-related considerations. Gather innovative ideas on how to align your business priorities with forward-looking trends and prepare for the future. LEARN MORE.
07.15.25 -- Finding Compatibility In Love And CDMO Partnerships
Just like people, some sponsor-CDMO partnerships can be matches made in heaven. Others, not so much. See what experts have to say about finding the right CDMO and building a successful partnership together. Analyzing The Need For An Engineering Run: A Risk-Based Decision Executing or skipping an engineering run is a consequential decision for any biopharma or CDMO and should be supported by all available data as well as a thorough risk assessment.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Hyeokgeon
Contact Hyeokgeon, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack